Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002222 · ClinicalTrials.gov registry record · NA
A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS
A NA study of HIV Infections and Cytomegalovirus Retinitis, sponsored by Hoffmann-La Roche.
- Completed
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT00002222: Completed NA study of HIV Infections and Cytomegalovirus Retinitis, sponsored by Hoffmann-La Roche.
NCT00002222 is a NA study of HIV Infections and Cytomegalovirus Retinitis that has completed, run by Hoffmann-La Roche. The registered enrollment target is 200 participants, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002222, a NA study of HIV Infections and Cytomegalovirus Retinitis, has completed, sponsored by Hoffmann-La Roche.
- COMPLETED
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to see if valganciclovir is a safe treatment for CMV retinitis in patients who have been treated for this condition in the past. This study also examines the effectiveness of valganciclovir in preventing the recurrence of CMV retinitis.
Conditions Studied
Interventions
- DRUG Valganciclovir
Study Locations (1)
New York
- Cornell AIDS Clinical Trials Unit - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Phase | NA |
What the finished NCT00002222 record still lists
NCT00002222 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 445-participant average among 542 other HIV Infections trials with a reported enrollment target (55% lower).
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 1 intervention - of which Valganciclovir is the first listed.
NCT00002222 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00002222 about?
NCT00002222 is a clinical study titled "A Study of Valganciclovir in the Treatment of Cytomegalovirus (CMV) Retinitis in Patients With AIDS". The purpose of this study is to see if valganciclovir is a safe treatment for CMV retinitis in patients who have been treated for this condition in the past. This study also examines the effectiveness of valganciclovir in preventing the recurrence of CMV retinitis.
What is the current status of trial NCT00002222?
This trial is currently completed. It is a NA study. The enrollment target is 200 participants.
What conditions does trial NCT00002222 study?
This clinical trial studies the following conditions: HIV Infections, Cytomegalovirus Retinitis.
What interventions are being tested in trial NCT00002222?
The interventions under investigation include: Valganciclovir (DRUG).
Who is sponsoring clinical trial NCT00002222?
This trial is sponsored by Hoffmann-La Roche, which has 909 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002222 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002222's enrollment target sits among peer trials
200 171st of 542 higher than 362 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
TRAC-ER Intervention to Reduce Risky Alcohol Use and HIV Risk
RECRUITING · NA
-
Community-based Education, Navigation, and Support Intervention for Military Veterans
RECRUITING · NA
-
WiseApp for Spanish Speakers Living With HIV
RECRUITING · NA
-
Comprehensive HIV and Harm Prevention Via Telehealth
RECRUITING · NA
-
Substance Checking Outreach and Pre-Exposure Prophylaxis (PrEP) Engagement Study
RECRUITING · NA
-
Food as Medicine for HIV and Diabetes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes